{"slug":"cml","tag":"cml","variants":["cml"],"description":"No description yet","count":3,"kinds":{"person":1,"biomarker":2},"related":[{"slug":"biomarker","tag":"biomarker","shared":2},{"slug":"australia","tag":"australia","shared":1},{"slug":"molecular-monitoring","tag":"molecular-monitoring","shared":1},{"slug":"resistance","tag":"resistance","shared":1}],"records":[{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","route":"/people/timothy-hughes/","tldr":"Defined molecular response monitoring in CML and showed that many patients can safely stop imatinib."},{"id":"bcr-abl1-transcript","kind":"biomarker","name":"BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)","route":"/biomarkers/bcr-abl1-transcript/","tldr":"The BCR::ABL1 fusion is the Philadelphia chromosome that defines chronic myeloid leukaemia and some acute lymphoblastic leukaemia. Its transcript level in blood, on the international scale, is how response to tyrosine kinase inhibitors is measured and when treatment can be stopped."},{"id":"bcr-abl1-t315i","kind":"biomarker","name":"BCR::ABL1 T315I","route":"/biomarkers/bcr-abl1-t315i/","tldr":"T315I is the gatekeeper mutation in the ABL1 kinase that defeats imatinib, dasatinib, nilotinib and bosutinib. Ponatinib and asciminib are the two drugs approved for it."}]}